fulvestrant has been researched along with Carcinoma, Ductal, Breast in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Takano, T; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, H; Yamashita, T; Yotsumoto, D | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Corbaux, P; Sabatier, R | 1 |
| Baena-Cañada, JM; Bayo, JL; Blancas, I; Bofill, JS; Carabantes, F; Conde, V; Cruz, J; Esquerdo, G; Fontanillas, M; García-Palomo, A; Gordon, MM; Illarramendi, JJ; Jaen, A; Jáñez, NM; Lao, J; Martínez, E; Mendiola, C; Pérez-Ruiz, E; Ruiz-Borrego, M; Sotelo, MJ | 1 |
| Kase, AM; Menke, D; Tan, W | 1 |
| Berger, D; Fattout, Y; Kazlauskaite, R; Usha, L; Waheed, S | 1 |
| Ali, S; Balasubramanian, S; Chenna, A; Chumsri, S; DeFazio-Eli, L; DeRidder, A; Goicocheal, L; Huang, W; Perez, EA; Wallweber, G; Weidler, J | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Alran, S; Balleyguier, C; Becette, V; Bourgier, C; Boussion, V; Cherel, P; Kerbrat, P; Lavau-Denes, S; Lemonnier, J; Lerebours, F; Martin, AL; Mathieu, MC; Mouret-Fourme, E; Mouret-Reynier, MA; Nabholz, JM; Rivera, S; Salmon, R; Sigal, B; Thibault, F; Trassard, M; Venat-Bouvet, L | 1 |
| Alonso Muñoz, A; García Alfonso, P; Martínez Marín, V; Muñoz Martín, AJ; Pérez Manga, G; Viñuela Benéitez, MC | 1 |
| Aranda, E; Berciano Guerrero, M; de la Haba Rodríguez, JR; Porras Quintela, I; Pulido Cortijo, G | 1 |
| Kelleher, SL; Lopez, V | 1 |
| Iwase, H; Iwata, H; Kamigaki, S; Masuda, N; Nakamura, S; Noguchi, S; Ohno, S; Rai, Y; Taniguchi, H; Yamamoto, N; Yoshida, M | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Jakesz, R; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Jordan, VC; Pink, JJ | 1 |
| Gornbein, J; Koeffler, HP; Miller, CW; Nakachi, K; O'Kelly, J; Said, JW; Sakashita, A; Xie, D | 1 |
1 review(s) available for fulvestrant and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Breast cancer metastasis to the bladder: a literature review.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cancer Survivors; Carcinoma, Ductal, Breast; Cystoscopy; Estradiol; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Urinary Bladder Neoplasms; Urinary Bladder, Overactive | 2018 |
3 trial(s) available for fulvestrant and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Female; Follow-Up Studies; France; Fulvestrant; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Triazoles | 2016 |
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Treatment Outcome | 2010 |
13 other study(ies) available for fulvestrant and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2020 |
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2020 |
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Resistance, Neoplasm; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2018 |
False Increase of Estradiol Levels in a 36-Year-Old Postmenopausal Patient With Estrogen Receptor-Positive Breast Cancer Treated With Fulvestrant.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromatography, Liquid; Estradiol; Estrogens; False Positive Reactions; Female; Fulvestrant; Humans; Immunoassay; Postmenopause; Receptors, Estrogen; Tandem Mass Spectrometry | 2016 |
Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Estradiol; Female; Fulvestrant; Humans; Mastectomy, Segmental; Middle Aged; Protein Kinase Inhibitors; Protein Multimerization; Receptor, ErbB-2; Retreatment; Trastuzumab | 2015 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
[Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Fulvestrant in advanced male breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Estradiol; Fulvestrant; Humans; Lung Neoplasms; Male; Mastectomy, Radical; Radiotherapy | 2009 |
Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells.
Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Ductal, Breast; Caspases; Cation Transport Proteins; Cell Count; Cell Line, Tumor; Epithelium; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mesoderm; Neoplasm Proteins; Reproducibility of Results; Tumor Stem Cell Assay; Zinc | 2010 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2007 |
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Ductal, Breast; DNA, Neoplasm; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Binding; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1996 |
Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Hormonal; Blotting, Northern; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cells, Cultured; Cysteine-Rich Protein 61; Disease Progression; DNA, Complementary; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Library; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Middle Aged; Multivariate Analysis; Neoplasm Transplantation; Promoter Regions, Genetic; Protein Binding; Receptors, Estrogen; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |